Epygenix Therapeutics, Inc. is developing precision medicine for rare and catastrophic forms of genetic epilepsy, such as Dravet Syndrome, Lennox-Gastaut Syndrome, Infantile Spasm, and Otahara syndrome.
How To Find Us
140 E. Ridgewood Ave.
Suite 415, South Tower
Paramus, NJ 07652
Phone: 1 (201) 940-7377
Fax: 1 (201) 940-7218
- Epygenix Therapeutics Initiates Phase 2 Study for Dravet Syndrome With EPX-100
- EpyGenix Launches Phase II Trial for EPX-100
- Epygenix Therapeutics Successfully Completes EPX-100 Phase I, Placebo-Controlled, Double-Blind, 2-Period Study and Ready to Phase 2 Studies
- Epygenix Therapeutics Receives IND Approval of EPX-100 for the Treatment of Dravet Syndrome